P. Westbrook et al., REGRESSION OF NIFEDIPINE-INDUCED GINGIVAL HYPERPLASIA FOLLOWING SWITCH TO A SAME CLASS CALCIUM-CHANNEL BLOCKER, ISRADIPINE, Journal of periodontology, 68(7), 1997, pp. 645-650
PATIENTS WITH NIFEDIPINE-INDUCED gingival hyperplasia (GH) often requi
re continued calcium channel blocker therapy. Switches to diltiazem an
d verapamil have been described; however, these drugs are of a differe
nt chemical class and present therapeutic limitations in some patients
. The purpose of this study was to evaluate the effect on nifedipine-i
nduced GH of a switch to a dihydropyridine derivative with a low incid
ence of GH. Fourteen patients with nifedipine-induced GH were given a
medical exam and a periodontal exam. The following parameters were ass
essed: probing depth (PD), gingival margin (GM), gingival thickness (G
T), plaque index (PI), and gingival index (GI). Intraoral photographs,
study models, and a gingival biopsy for histological examination were
taken. Following baseline measures, patients were randomized to conti
nued treatment with nifedipine or an equivalent dose of isradipine in
a single-blind fashion. Biweekly periodontal parameters were taken for
8 weeks. At the end of 8 weeks, some patients elected to receive 4 we
eks of open label isradipine therapy, with biweekly examination contin
uing through the open label phase. The isradipine treatment arm showed
a mean decrease in PD of 0.59 mm at week 8 (P < 0.05). No other measu
red parameter (GM, GT, PI, GI) was significantly changed, compared eit
her to baseline or to the alternate treatment arm. Clinically, 60% of
patients treated with isradipine exhibited a decrease in hyperplasia,
while 66% of patients treated with nifedipine demonstrated an increase
in hyperplasia, a significant difference (F < 0.05). When combined wi
th open label data, patients switching therapy to isradipine exhibited
an increase in GM (increase in recession) of 0.74 mm from baseline to
week 12 (P < 0.05). No patients treated with isradipine exhibited an
increase in gingival overgrowth. All patients exhibited adequate contr
ol of hypertension. We conclude that in hypertensive patients with nif
edipine-induced GH, switching hypertensive therapy to isradipine may r
esult in a regression of GH. When coupled with aggressive oral hygiene
treatment, this drug may provide a reasonable option for patients req
uiring dihydropyridine treatment.